AstraZeneca's Blood Pressure Drug Approved in U.S

• Baxfendy targets hormonal causes of hypertension by inhibiting aldosterone production, differentiating it from older treatments like diuretics and ACE inhibitors that don't address hormonal drivers
• Clinical trial data showed the drug reduced systolic blood pressure by 8.7-9.8 mmHg at 12 weeks when added to standard treatment in patients with resistant hypertension
• The approval puts AstraZeneca ahead of competitor Mineralys Therapeutics, whose rival drug lorundrostat is under FDA review with a decision expected in December 2025

AstraZeneca's Blood Pressure Drug Approved in U.S. - Summary

Key Development:

AstraZeneca announced Monday that the FDA has approved its hypertension drug baxdrostat (branded as Baxfendy) for use in the United States. The drug targets patients with uncontrolled high blood pressure despite existing medications and will be used in combination with other antihypertensive treatments.

Financial Projections:

AstraZeneca expects Baxfendy to generate more than $5 billion in peak annual sales. The company acquired the drug through its $1.8 billion acquisition of CinCor Pharma in February 2023.

Market Context:

Hypertension affects approximately 1.4 billion people globally and nearly 120 million U.S. adults—about half the adult population. The approval positions AstraZeneca ahead of competitor Mineralys Therapeutics, whose rival drug lorundrostat is under FDA review with a decision expected in December.

Mechanism of Action:

Baxfendy works by blocking aldosterone production, a hormone that raises blood pressure and increases heart and kidney disease risk. This represents a different approach from traditional treatments like diuretics and ACE inhibitors, which don't address hormonal causes. The drug is also being studied for chronic kidney disease and heart failure.

Clinical Data:

FDA approval was based on late-stage study results showing significant blood pressure reduction in resistant hypertension patients. At 12 weeks, the 2 mg dose reduced systolic blood pressure by 9.8 mmHg from baseline (placebo-adjusted), while the 1 mg dose achieved an 8.7 mmHg reduction.

Market Implications:

The approval addresses a significant unmet medical need in cardiovascular care and strengthens AstraZeneca's position in the lucrative hypertension treatment market.